COMPASS Pathways plc (CMPS) Form 8-K — Aug 5, 2026
COMPASS Pathways reported a Q2 2026 net loss of $253.8 million, or $1.88 per share, versus $38.4 million a year earlier, driven primarily by a $205.6 million non-cash fair value loss on warrant liabilities rather than operational deterioration. First-half 2026 net loss was $162.6 million, or $1.33 per share. The company ended the quarter with $433.3 million in cash, up from $149.6 million at year-end 2025, and guided that the position funds operations into 2028 — well beyond its targeted first-half 2027 commercial launch of COMP360, which remains subject to FDA approval and DEA rescheduling.
Key figures
- Eps
- -$1.88 (Q2 2026); -$1.33 (1H 2026)
- Guidance
- Current cash position expected to be sufficient to fund operating expenses and capital expenditure requirements into 2028
- Net Income
- -$253.8 million (Q2 2026); -$162.6 million (1H 2026)
- Total Debt
- 50700000
- Total Assets
- 504561000
- Cash Position
- 433300000
- Us trd patients
- approximately 4 million
- Cash dec 31 2025
- $149.6 million
- Net loss q2 2025
- $38.4 million
- Ga expense q2 2026
- $23.2 million (vs $12.6 million Q2 2025)
- Phase3 participants
- more than 1,000
- Rnd expense h1 2026
- $55.7 million (vs $61.2 million H1 2025)
- Rnd expense q2 2026
- $29.2 million (vs $30.3 million Q2 2025)
- Nda final submission
- Q4 2026
- Npv review potential
- 1-2 months
- Commercial launch expected
- first half of 2027
- Net loss per share q2 2025
- -$0.41
- Shares outstanding dec 31 2025
- 96085785
- Shares outstanding jun 30 2026
- 135722306
- Shareholders equity jun 30 2026
- $84.5 million
- Warrant fair value loss q2 2026
- $205.6 million
- Warrant liabilities jun 30 2026
- $337.5 million
Price after filing
Close on the filing date to close N calendar days later (from $11.80). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.